SGMO SANGAMO THERAPEUTICS, INC: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $107K on the open market; over its last four quarters it reported revenue of $34.6M and net income of −$123M.
SGMO revenue and earnings
- Quarter ended Mar 31, 2026: revenue $1.44M, net income −$31.0M, EPS -0.08
- Quarter ended Dec 31, 2025: revenue $14.2M, net income −$37.4M, EPS -0.11
- Quarter ended Sep 30, 2025: revenue $581K, net income −$34.9M, EPS -0.11
- Quarter ended Jun 30, 2025: revenue $18.3M, net income −$20.0M, EPS -0.08
Recent SGMO insider trades
- Apr 22, 2026: Davis Gregory D sold 69,827 shares ($17.5K)
- Apr 21, 2026: Dubois-Stringfellow Nathalie sold 345,942 shares ($89.9K)
5%+ owners
- Armistice Capital, LLC: 9.4% (Schedule 13G/A, filed Aug 14, 2026)
Are insiders buying or selling SGMO?
Over the last 12 months insiders bought $0 and sold $107K of SANGAMO THERAPEUTICS, INC stock on the open market (SEC Form 4).
What was SGMO's revenue last quarter?
SANGAMO THERAPEUTICS, INC reported revenue of $1.44M for the quarter ended March 31, 2026, with net income of −$31.0M.